Your browser doesn't support javascript.
loading
Co-targeting BCL-XL and BCL-2 by PROTAC 753B eliminates leukemia cells and enhances efficacy of chemotherapy by targeting senescent cells.
Jia, Yannan; Han, Lina; Ramage, Cassandra L; Wang, Zhe; Weng, Connie C; Yang, Lei; Colla, Simona; Ma, Helen; Zhang, Weiguo; Andreeff, Michael; Daver, Naval; Jain, Nitin; Pemmaraju, Naveen; Bhalla, Kapil; Mustjoki, Satu; Zhang, Peiyi; Zheng, Guangrong; Zhou, Daohong; Zhang, Qi; Konopleva, Marina.
Afiliação
  • Jia Y; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Hematology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai.
  • Han L; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Ramage CL; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Wang Z; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Weng CC; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Yang L; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Colla S; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Ma H; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Zhang W; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Andreeff M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Daver N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Jain N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Pemmaraju N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Bhalla K; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Mustjoki S; Hematology Research Unit Helsinki, University of Helsinki and Helsinki University Hospital Comprehensive Cancer center, Helsinki, Finland; Translational Immunology Research Program and Department of Clinical Chemistry and Hematology, University of Helsinki, Helsinki, Finland; iCAN Digital Precision
  • Zhang P; Department of Medicinal Chemistry, College of Pharmacy, University of Florida, Gainesville, FL.
  • Zheng G; Department of Medicinal Chemistry, College of Pharmacy, University of Florida, Gainesville, FL.
  • Zhou D; Department of Biochemistry and Structural Biology and Center for Innovative Drug Discovery, Long School of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX.
  • Zhang Q; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX. qzhang9@mdanderson.org.
  • Konopleva M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX. mkonople@mdanderson.org.
Haematologica ; 108(10): 2626-2638, 2023 10 01.
Article em En | MEDLINE | ID: mdl-37078252
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Leucemia Mieloide Aguda / Antineoplásicos Limite: Humans Idioma: En Revista: Haematologica Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Leucemia Mieloide Aguda / Antineoplásicos Limite: Humans Idioma: En Revista: Haematologica Ano de publicação: 2023 Tipo de documento: Article